Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 2,250 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 2,250 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $60.90, for a total transaction of $137,025.00. Following the sale, the executive vice president owned 145,435 shares of the company’s stock, valued at $8,856,991.50. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, October 5th, Jim Wassil sold 18,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.74, for a total value of $1,561,320.00.
• On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.67, for a total value of $127,507.50.
• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total value of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total value of $212,340.39.

Vaxcyte Trading Up 8.0%

Shares of Vaxcyte stock opened at $65.68 on Thursday. Vaxcyte, Inc. has a 1 year low of $39.87 and a 1 year high of $90.75. The company’s fifty day simple moving average is $61.64 and its 200-day simple moving average is $57.16. The company has a market cap of $9.77 billion, a price-to-earnings ratio of -8.61 and a beta of 1.31.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, November 4th. The company reported ($1.99) EPS for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same quarter last year, the firm earned ($1.56) EPS. As a group, research analysts forecast that Vaxcyte, Inc. will post -7.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PCVX. Guggenheim upped their price objective on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Bank of America lowered their price target on Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research note on Monday, September 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, October 2nd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $89.00 price target on shares of Vaxcyte in a report on Monday, October 5th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vaxcyte has an average rating of “Moderate Buy” and an average target price of $110.50.

Hedge Funds Weigh In On Vaxcyte

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jupiter Topco LLC bought a new stake in Vaxcyte in the second quarter valued at about $1,044,355,000. Janus Henderson Group PLC raised its position in Vaxcyte by 23.8% in the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after purchasing an additional 3,188,687 shares in the last quarter. BlackRock Inc. bought a new position in Vaxcyte during the second quarter worth about $701,520,000. Wellington Management Group LLP lifted its stake in Vaxcyte by 24.7% during the second quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock worth $407,001,000 after purchasing an additional 1,386,968 shares during the period. Finally, Jennison Associates LLC lifted its stake in Vaxcyte by 150.6% during the first quarter. Jennison Associates LLC now owns 1,698,011 shares of the company’s stock worth $98,671,000 after purchasing an additional 1,020,458 shares during the period. 96.78% of the stock is owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.